Recruitment is underway for a medical trial testing a vaccine candidate produced with The College of Queensland’s molecular clamp know-how towards life-threatening respiratory viruses.
Vicebio, the vaccine firm licensed to develop the UQ know-how, has developed a brand new candidate vaccine to battle respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).
Each viruses trigger respiratory tract illnesses which can be extreme, particularly in kids beneath the age of 5, in adults and the aged in addition to in immunocompromised people.
UQ virologist Professor Keith Chappell, co-inventor of the molecular clamp, stated the trial is being facilitated by the College of the Sunshine Coast’s (UniSC) Scientific Trials community throughout 3 devoted trial centres in Southeast Queensland, together with Brisbane, the Sunshine Coast and Moreton Bay areas.
“Each RSV and hMPV infections have surged all through Australia in recent times and there’s a actual have to discover new proactive safety and prevention choices,” Professor Chappell stated.
“It’s thrilling to see this home-grown know-how used to develop a singular vaccine to doubtlessly forestall respiratory sickness attributable to these two viruses.
Vicebio Chief Govt Officer Emmanuel Hanon stated the Section I trial would decide the protection and immunogenicity of the vaccine in comparison with a lately licensed RSV vaccine.
RSV and hMPV trigger substantial hospitalizations and well being issues for our older grownup group.
The progressive Vicebio vaccine candidate may very well be a turning level in lowering the burden of illness related to respiratory viruses, particularly in weak populations.”
Dr. Emmanuel Hanon, Vicebio Chief Govt Officer
120 older adults aged 60 to 83 are wanted for the medical trial being coordinated by UniSC Scientific Trials.
Principal Investigator Dr Nischal Sahai stated contributors have to be in good well being and meet key standards to be eligible for the examine.
“Trial volunteers should not have had a documented RSV and/or hMPV an infection within the earlier 12 months and shall be paid for his or her time on the trial.,” Dr Sahai stated.
“I ought to stress that ‘good well being’ permits for a lot of well-controlled continual situations and we hope that members of the group will assist this essential undertaking.”
UQ’s commercialization firm UniQuest solely licensed the clamp know-how to Vicebio for non-epidemic use.
Proof-of-concept testing final yr cleared the way in which to progress the know-how for use in a variety of analysis applications.
For additional data or to register your curiosity, go to UniSC Scientific Trials.
Supply:
The College of Queensland
